VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-89303 | Pharmaceuticals and Healthcare
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET
7.1 GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA VIRAL VECTORS, NON-VIRAL VECTORS AND GENE THERAPY MANUFACTURING MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 BioReliance
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Cobra Biologics
16.3 Oxford BioMedica
16.4 UniQure
16.5 FinVector
16.6 MolMed
16.7 MassBiologics
16.8 Richter-Helm
16.9 FUJIFILM Diosynth Biotechnologies
16.10 Lonza
16.11 Aldevron
16.12 Eurogentec
16.13 Cell and Gene Therapy Catapult
16.14 Biovian
16.15 Thermo Fisher Scientific (Brammer Bio)
16.16 VGXI
16.17 PlasmidFactory
16.18 bluebird bio
16.19 Novasep
16.20 Spark Therapeutics
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeAAV
Adenoviral
Lentiviral
Retroviral
Plasmid DNA
Other Vectors
By Application
Cancers
Inherited Disorders
Viral Infections
Companies
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
bluebird bio
Novasep
Spark Therapeutics
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.